SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): June 8, 2006

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

000-31979

84-1460811

(State or Other

(Commission

(IRS Employer

Jurisdiction of

File Number)

Identification No.)

Incorporation)

 

 

 

 

 

3200 Walnut Street, Boulder, Colorado

80301

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s telephone number, including area code:  (303) 381-6600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

                        o                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

                        o                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

                        o                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

                        o                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

ITEM 8.01. OTHER EVENTS

 

On June 8, 2006, AstraZeneca and Array BioPharma Inc. issued a joint press release announcing the initiation of a Phase II study for AZD6244 (ARRY-142886) in malignant melanoma. AstraZeneca expects the first patient to be enrolled in this melanoma study before the end of June, which will trigger a $3 million milestone payment from AstraZeneca to Array upon dosing the first patient. The full text of this joint press release is attached hereto as Exhibit 99.1.

 

 

 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits.

 

99.1           Press release dated June 8, 2006 entitled “AstraZeneca and Array BioPharma Announce Initiation of Phase II Studies for AZD6244 (ARRY-142886).”

 

2


 

SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ARRAY BIOPHARMA INC.

 

 

 

Date: June 8, 2006

By:

/s/ Robert E. Conway

 

 

Robert E. Conway

 

 

Chief Executive Officer

 

 

3


 

EXHIBIT INDEX

 

Exhibit No.

 

 

 

 

 

99.1

 

Press release dated June 8, 2006 entitled “AstraZeneca and Array BioPharma Announce Initiation of Phase II Studies for AZD6244 (ARRY-142886).”

 

4